Press Releases

Canadian Patent for Adipose Stem Cells Issued Under Vet-Stem License

2014-06-20 --

Vet-Stem, Inc. announced that another patent has issued under its exclusive worldwide license with Artecel, Inc. and with The University of California.  This patent covers compositions of adipose tissue-derived stem cells that can differentiate into many types of tissues that include cartilage, bone, nerve, kidney, heart and skin.  This patent will provide coverage for the on-going commercial and development programs at Vet-Stem. 

This new patent adds to the other patents in the Vet-Stem portfolio that cover compositions and methods of production of regenerative cells from adipose tissue for many diseases in humans and animals.  Vet-Stem has exclusive worldwide rights for veterinary use of these patents (over 50 issued and 70 pending patents) which improves the company's intellectual property position in this rapidly developing field.

As the first company in the United States to provide an adipose-derived stem cell service to veterinarians for their patients, Vet-Stem, Inc. pioneered the use of regenerative stem cells in veterinary medicine.  In the last decade over 10,000 animals including horses, dogs, cats, and some exotics have been treated using Vet-Stem’s services.

"Intellectual property rights are key assets in these markets and our investments in the area over the last decade have created tremendous value for our shareholders," said Robert Harman, DVM, MPVM, CEO and Founder of Vet-Stem.  "We need to do everything possible to protect and grow the market that we are creating in Regenerative Veterinary Medicine by providing the highest quality control in the industry.  The value of this technology has increased greatly since the founding of the company in 2002 by providing clear evidence of the therapeutic activity and safety of these stem cells."

Vet-Stem researchers have been authors on 11 peer-reviewed papers including the first blinded, controlled, multicenter study of adipose-derived stem cells for chronic osteoarthritis in the canine hip joint, and the first multicenter clinical study of adipose-derived stem cells for chronic osteoarthritis in the canine elbow.  Vet-Stem is actively investigating stem cell therapy for immune-mediated and inflammatory disease, as well as organ disease and failure. 

About Vet-Stem, Inc.

Vet-Stem, Inc. was formed in 2002 to bring regenerative medicine to the veterinary profession.  The privately held company is working to develop therapies in veterinary medicine that apply regenerative technologies while utilizing the natural healing properties inherent in all animals.  The company holds exclusive licenses to over 50 patents including world-wide veterinary rights for use of adipose derived stem cells.